Managing Alzheimer's Trials In A Diverse Global Environment

Treatment for patients suffering from Alzheimer’s Disease can differ both around the world and around the block. For example, on a global level, there are differences in diagnostic criteria for the disease in guiding care for individual patients. And, at the local level, there may be racial and ethnic disparities that prevent both treatment and disease education. These factors can lead to the development of vastly different standards of care, clinical trial results that underrepresent patient demographics, and poor deployment and commercialization of life-saving treatments across country lines – all of which can have a profound effect on executing international clinical trials and maintaining standardized protocols. In this article read how recognizing the common disparities for these clinical trials, ranging from standards of care to lack of diversity, brings sponsors and other stakeholders closer to maintaining standardized protocols for Alzheimer’s studies.